This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
FibroGen (FGEN) Q3 Earnings Beat Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of 139.33% and -10.19%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Akebia Falls as Vadadustat Fails to Meet Safety Endpoint
by Zacks Equity Research
Akebia (AKBA) posts top-line data from two phase III studies, namely PRO2TECT, which are evaluating vadadustat for treating anemia due to chronic kidney disease in adults not on dialysis. Shares down.
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of -61.02% and 22.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: FibroGen (FGEN) Q2 Earnings Expected to Decline
by Zacks Equity Research
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Theravance Doses First Patient in Phase II Coronavirus Study
by Zacks Equity Research
Theravance (TBPH) initiates dosing in a mid-stage study, evaluating its JAK inhibitor TD-0903 for the potential treatment of hospitalized patients with acute lung injury due to COVID-19.
FibroGen Begins Phase II Study for Acute Coronavirus in US
by Zacks Equity Research
FibroGen (FGEN) enrolls the first patient in a placebo-controlled phase II study on pamrevlumab in hospitalized patients with acute COVID-19 infection in the United States.
FibroGen (FGEN) in Focus: Stock Moves 6.5% Higher
by Zacks Equity Research
FibroGen (FGEN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
FibroGen Initiates Phase II/III Study in Severe Coronavirus
by Zacks Equity Research
FibroGen (FGEN) starts a phase II/III study in Italy on pamrevlumab versus standard of care in patients with severe COVID-19 infection.
AstraZeneca Inks Deal to Develop RMP Inhibitors for Cancer
by Zacks Equity Research
AstraZeneca (AZN) signs an oncology agreement with Accent Therapeutics to develop novel therapies targeting RNA-modifying proteins for treating cancer.
FibroGen (FGEN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of -196.67% and -64.10%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Why FibroGen (FGEN) Might Surprise This Earnings Season
by Zacks Equity Research
FibroGen (FGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AstraZeneca's Lokelma Gets Approval in Japan for Hyperkalaemia
by Zacks Equity Research
The Japanese regulatory body nods to AstraZeneca's (AZN) Lokelma for addressing patients with hyperkalaemia. The company collaborates with Silence Therapeutics for siRNA therapeutics.
FibroGen (FGEN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of -80.65% and -74.01%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate FibroGen (FGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis' (ZTS) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Zoetis (ZTS) beats on both earnings and sales in the fourth quarter of 2019.
FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA
by Zacks Equity Research
The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.
Are Options Traders Betting on a Big Move in FibroGen (FGEN) Stock?
by Zacks Equity Research
Investors need to pay close attention to FibroGen (FGEN) stock based on the movements in the options market lately.
FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of 3.39% and 8.13%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
FibroGen (FGEN) Soars: Stock Adds 9.6% in Session
by Zacks Equity Research
FibroGen (FGEN) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Mallinckrodt (MNK) Q3 Earnings Beat, Stock Down on Sales Miss
by Zacks Equity Research
Mallinckrodt (MNK) misses on sales but beats on earnings in the third quarter of 2019.
Jazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives Sales
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) beats third-quarter 2019 earnings and revenue estimates and raises its guidance for 2019.
Karyopharm (KPTI) Catches Eye: Stock Jumps 6.4%
by Zacks Equity Research
Karyopharm (KPTI) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Bausch (BHC) Beats on Q3 Earnings & Sales, Raises Guidance
by Zacks Equity Research
Bausch (BHC) beats on sales and earnings in the third quarter and raises annual guidance.
Endo (ENDP) Q3 Earnings & Revenues Beat Estimates, Down Y/Y
by Zacks Equity Research
Endo (ENDP) reports better-than-expected results for the third quarter as Xiaflex delivers a strong performance.